Replimune Group Inc (NASDAQ:REPL) Short Interest Update

Replimune Group Inc (NASDAQ:REPL) was the target of a significant drop in short interest in November. As of November 29th, there was short interest totalling 663,200 shares, a drop of 15.5% from the November 14th total of 784,700 shares. Based on an average trading volume of 140,500 shares, the days-to-cover ratio is currently 4.7 days. Approximately 8.7% of the company’s stock are sold short.

NASDAQ REPL traded up $0.07 on Friday, reaching $15.28. 123,438 shares of the company were exchanged, compared to its average volume of 278,755. The business’s fifty day moving average price is $14.72 and its 200 day moving average price is $13.20. The stock has a market capitalization of $473.73 million, a P/E ratio of -11.49 and a beta of 3.06. The company has a current ratio of 9.85, a quick ratio of 9.85 and a debt-to-equity ratio of 0.16. Replimune Group has a fifty-two week low of $8.88 and a fifty-two week high of $18.25.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). Equities research analysts forecast that Replimune Group will post -1.38 earnings per share for the current year.

In other Replimune Group news, CEO Robert Coffin sold 24,250 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $413,462.50. Also, COO Colin Love sold 11,250 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $191,812.50. In the last three months, insiders acquired 1,335,000 shares of company stock valued at $18,016,500 and sold 200,000 shares valued at $3,395,500. 63.18% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its stake in shares of Replimune Group by 34.6% in the 3rd quarter. Squarepoint Ops LLC now owns 21,799 shares of the company’s stock valued at $303,000 after purchasing an additional 5,599 shares during the last quarter. Morgan Stanley lifted its stake in shares of Replimune Group by 793.0% in the 2nd quarter. Morgan Stanley now owns 20,709 shares of the company’s stock valued at $304,000 after purchasing an additional 18,390 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Replimune Group by 211.3% in the 2nd quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after purchasing an additional 15,672 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Replimune Group by 1.2% in the 2nd quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after buying an additional 1,437 shares during the period. Finally, State Street Corp raised its holdings in shares of Replimune Group by 6.0% in the 3rd quarter. State Street Corp now owns 183,687 shares of the company’s stock valued at $2,553,000 after buying an additional 10,406 shares during the period. 56.99% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on REPL shares. Chardan Capital reaffirmed a “buy” rating and set a $28.00 target price on shares of Replimune Group in a report on Thursday, October 24th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Replimune Group in a report on Monday, September 30th. ValuEngine downgraded Replimune Group from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research downgraded Replimune Group from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Wedbush decreased their target price on Replimune Group from $30.00 to $12.50 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $23.25.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: Call Option

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.